• 100units/ml suspension for injection 10ml vial

• Approved Humulin® I formulations include:
  
  • 5x3ml cartridges;
  • 5x3ml pens. 

• First choice long acting basal insulin in patients eligible for treatment in line with NICE and NTAG
• Approved Abasaglar® formulations include:
  
  • 5x3ml cartridge
  • 5x3ml Kwikpen®.
  
  

• 100 units/mL
• Pre-filled pen and cartridges
• Approved for use in patients with Type 1 diabetes with
  
  • Nocturnal/Severe Hypogycaemia (with or without hypoglycaemic unawareness) in patients who would otherwsie progress to insuling pump treatment as per NICE TA151); or
  • Recurrent DKA episodes despite good compliance and who would otherwise progress to insulin pump therapy
  • Paediatric patients who cannot tolerate glargine sting
  • Paediatric patients with poor control on the high HbA1c pathway
  • Patients or Parents/Carers with unpredictable lifestyles such as students or shift workers.

“**Note that there are two strengths of Tresiba® (insulin degludec). Caution should be exercised when prescribing and dispensing**

• 200 units/mL
• Pre-filled pen
• Approved for use in patients with Type 1 diabetes with
  
  • Nocturnal/Severe Hypogycaemia (with or without hypoglycaemic unawareness) in patients who would otherwise progress to insulin pump treatment as per NICE TA151; or
  • Recurrent DKA episodes despite good compliance and who would otherwise progress to insulin pump therapy
  • Paediatric patients who cannot tolerate glargine sting
  • Paediatric patients with poor control on the high HbA1c pathway
  • Patients or Parents/Carers with unpredictable lifestyles such as students or shift workers.

**Note that there are two strengths of Tresiba^® (insulin degludec). Caution should be exercised when prescribing and dispensing**

• Alternative choice long acting basal insulin.
• Approved Levemir® formualtions include:
  
  • 5x3ml cartridges;
  • 5x3ml pens. 

NB: This product is being discontinued (stock expected to be exhausted by December 2026). No new patients should be initiated on this product

• Alternative choice long acting basal insulin. 
• Approved Lantus® formulations include:
  
  • 10ml vials;
  • 5x3ml cartridges;
  • 5x3ml pens (Solostar® - in line with NICE). 

• Alternative choice long acting basal insulin.
• Approved Toujeo® formulations include:
  • 1.5mL pre-filled pen (Solostar): Dose range 1-80 units in 1 unit increments. 450 units in a pen
  • 3mL pre-filled pen (DoubleStar): Dose range 2-160 units in 2 unit increments. 900 units in a pen.

**CARE: HIGH STRENGTH INSULIN**

Approved for use in patients on insulin glargine who require:

• High dose (60+ units per dose for Toujeo SoloStar and 80+ units per dose for DoubleStar
• Large volume of insulin and local site reactions
• Twice daily insulin

NOTE: Toujeo 300 units/ml is not bioequivalent to insulin glargine 100 units/ml and is not directly interchangeable